Signal detection in small pharma: what you actually need to do

A Phase 2 oncology company with 80 patients enrolled receives a spontaneous report from a study investigator about an unexpected case of severe peripheral neuropathy. Is this a signal? How do you know? And who is responsible for figuring it out? The answer, per GVP Module IX, is that the sponsor is responsible — regardless of how small they are.

What constitutes a signal

The ICH E2C(R2) guideline defines a signal as information that arises from one or multiple sources, including observations and experiments, which suggests a new potentially causal association, or a new aspect of a known association, between an intervention and an event or set of related events, either adverse or beneficial, that is judged to be of sufficient likelihood to justify verificatory action.

In plain terms: a signal is a hypothesis, not a confirmed risk. It says something might be happening. Signal detection is the process of systematically looking for these hypotheses before they become confirmed serious risks — or before regulators find them first.

Methods for small pharma

Large pharma uses statistical disproportionality analysis — methods like Proportional Reporting Ratio (PRR) or Empirical Bayes Geometric Mean (EBGM) — across databases with millions of reports. Small pharma with a single investigational compound does not need this. What you need is a documented, systematic review process applied to all available data sources:

• Clinical trial data — systematic review of all SAE listings, hospitalisation rates, and laboratory abnormalities across all ongoing and completed studies
• Published literature — monthly searches of PubMed, Embase, and relevant conference abstracts for reports involving your drug class or mechanism
• Regulatory authority databases — periodic review of FAERS and EudraVigilance for spontaneous reports involving products with similar mechanisms or structures
• Investigator reports and communications — systematic logging and review of all safety-related queries from study investigators

Signal assessment and action

When a potential signal is identified, it must be assessed. Assessment involves determining whether the signal is new (not described in the current Investigator Brochure or label), clinically significant, and whether the available evidence supports causality. The outcome of signal assessment is documented and may lead to: an expedited report to authorities, an urgent safety measure (e.g., protocol amendment, IB update), or a conclusion that the signal is not validated and requires continued monitoring.

GVP Module IX Section V requires the MAH to submit detected and validated signals to competent authorities as part of PSURs. For clinical sponsors, significant safety findings trigger IB updates and IND safety reports.

Signal detection does not require a large team. It requires a structured process, documentation, and a qualified person to oversee it. Nimble PV builds signal detection frameworks for Phase 1-3 sponsors. Talk to Vera at nimblepv.com.